

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7600437

SUBMISSION TYPE:	RESUBMISSION
NATURE OF CONVEYANCE:	ASSIGNMENT
RESUBMIT DOCUMENT ID:	507486783
CONVEYING PARTY DATA	
Name	Execution Date
ROLAND BÜRLI	03/03/2017
RECEIVING PARTY DATA	
Name:	MEDIMMUNE LIMITED
Street Address:	MILSTEIN BUILDING
Internal Address:	GRANTA PARK
City:	CAMBRIDGE
State/Country:	UNITED KINGDOM
Postal Code:	CB21 6GH
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17868856
CORRESPONDENCE DATA	
Fax Number:	(301)576-6932
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3013983000
Email:	patents@astrazeneca.com
Correspondent Name:	ASTRAZENECA
Address Line 1:	ONE MEDIMMUNE WAY
Address Line 2:	INTELLECTUAL PROPERTY DEPT.
Address Line 4:	GAITHERSBURG, MARYLAND 20878
ATTORNEY DOCKET NUMBER:	200905-US-CNT[2]
NAME OF SUBMITTER:	DENISE COOPER
SIGNATURE:	/Denise Cooper/
DATE SIGNED:	10/20/2022
Total Attachments: 6	
source=Burli#page1.tif	
source=20180809_Assignment Roland Burli to MedImmune Limited#page1.tif	
source=20180809_Assignment Roland Burli to MedImmune Limited#page2.tif	

source=20180809_Assignment Roland Burli to MedImmune Limited#page3.tif
source=20180809_Assignment Roland Burli to MedImmune Limited#page4.tif
source=20180809_Assignment Roland Burli to MedImmune Limited#page5.tif

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7533673

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ROLAND BÜRLI	03/03/2017
RECEIVING PARTY DATA		
Name:	MEDIMMUNE LIMITED	
Street Address:	MILSTEIN BUILDING	
Internal Address:	GRANTA PARK	
City:	CAMBRIDGE	
State/Country:	UNITED KINGDOM	
Postal Code:	CB21 6GH	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	17868856
CORRESPONDENCE DATA		
Fax Number:	(301)576-6932	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	3013983000	
Email:	patents@astrazeneca.com	
Correspondent Name:	ASTRAZENECA	
Address Line 1:	ONE MEDIMMUNE WAY	
Address Line 2:	INTELLECTUAL PROPERTY DEPT.	
Address Line 4:	GAITHERSBURG, MARYLAND 20878	
ATTORNEY DOCKET NUMBER:	200905-US-CNT[2]	
NAME OF SUBMITTER:	DENISE COOPER	
SIGNATURE:	/Denise Cooper/	
DATE SIGNED:	09/12/2022	
Total Attachments: 5		
source=20180809_Assignment Roland Burli to MedImmune Limited#page1.tif		
source=20180809_Assignment Roland Burli to MedImmune Limited#page2.tif		
source=20180809_Assignment Roland Burli to MedImmune Limited#page3.tif		
source=20180809_Assignment Roland Burli to MedImmune Limited#page4.tif		

THIS CONFIRMATORY ASSIGNMENT is made as of the date of the last signature below (the "Effective Date")

BY AND BETWEEN

Roland Bürli, a citizen of Switzerland, c/o MedImmune Limited, Aaron Klug Building, Granta Park, Cambridge, CB21 6GH, United Kingdom (the "Inventor(s)")

AND

MEDIMMUNE LIMITED, with registered office address at Aaron Klug Building, Granta Park, Cambridge, CB21 6GH, United Kingdom ("MedImmune")

Recitals

WHEREAS

- A. The Inventor(s) have made certain inventions (the "Inventions") in respect of which the patent application(s) specified in the attached Schedule have been filed (the "Patent Application(s)").
- B. The Inventor(s) was/were at all relevant times an employee of MedImmune.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. In consideration of the amounts paid to the Inventor(s) pursuant to their contract of employment with MedImmune, the Inventor(s) hereby confirm(s) that by virtue of their employment with MedImmune they have assigned, and in so far as there may be any outstanding rights that have not been assigned to MedImmune do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to MedImmune absolutely their entire right, title and interest in and to the Inventions, the Patent Application and any patents derived therefrom (collectively the "Patents"); any divisions, continuations and continuations-in-part of the Patents; any re-issues, re-examinations, or extensions of any and all Patents; the right to file patent applications directly in the name of MedImmune or an affiliated company of MedImmune (in countries or regions where such filings are permissible); and the right to claim priority rights deriving from the Patents (collectively, the "Rights"), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Inventor(s) warrant(s) that the Rights are unencumbered. The Inventor(s) acknowledge(s) that MedImmune shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and the Inventor(s) waive(s) any right of first refusal that they may have for acquiring such Rights.
2. The Inventor(s) each hereby agree(s) with MedImmune that their assignment to MedImmune includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Patents, including all rights to recover damages, profits and injunctive relief for infringement of any of the Patents, and the right to file a patent application anywhere in the world claiming convention priority.
3. The Inventor(s) each hereby agree(s) with MedImmune that they will execute such further documents and give such assistance at the expense of MedImmune as MedImmune may require:
 - a) to secure the vesting in MedImmune of all rights in the Patents and in such parties to whom MedImmune may assign its rights in the Patents;
 - b) to defeat any challenge to the validity of and resolve any questions concerning the Patents; and

60709523_1

- c) to apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Patents, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. The Inventor(s), on behalf of itself and its successors, assigns, nominees, or other legal representatives, does hereby covenant and agree with MedImmune that they shall, at the expense of MedImmune, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by MedImmune to enable MedImmune or its successors, nominees or assigns to enjoy the full benefit of the rights assigned by this agreement.
5. MedImmune accepts the above assignment.
6. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.


This agreement has been entered into on the Effective Date.

Signed at: CAMBRIDGE, UK

Date: March 3, 2017

R. Bürl
Name: Roland Bürl

On this 3rd day of MARCH, 2017, before me, the undersigned notary public, personally appeared Roland Bürl, proved to me through satisfactory evidence of identification which was Passport No. X45 05578, to be the person whose name is signed on the preceding or attached document in my presence.



My commission expires WITH LIFE

Neil Roger Burton
Notary Public

NEIL ROGER BURTON
Notary Public
100 Hills Road, Cambridge
CB2 1PH, England

My commission expires with life

60709523_1

Signed at: CAMBRIDGE, UK


Signed for and on behalf of
MEDIMMUNE LIMITED

Signature: _____
Name: _____


Title: Authorised Signatory

Date: 03 MARCH 2017

On this 3rd day of MARCH, 2017, before me, the undersigned notary public, personally appeared FRADER Ewing NELSON, proved to me through satisfactory evidence of identification which was UK Driving Licence No. NELSON 70423336 XY48, to be the person whose name is signed on the preceding or attached document in my presence.



My commission expires with LIFE



Notary Public

NEIL ROGER BURTON
Notary Public
100 Hills Road, Cambridge
CB2 1PH, England

My commission expires with life

60709523_1

THE SCHEDULE

THE PATENT APPLICATION(S)					
Application No.: (R&G Case No.)	Application Ref:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
20170100338 (110421-0087-AR1)	A	Argentina	National	HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS	10-Feb-2017
(110421-0087-BO1)	B	Bolivia	National	HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS	
(110421-0087-BS1)	C	Bahamas	National	HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS	
ET/P/2017/358 (110421-0087-ET1)	D	Ethiopia	National	HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS	10-Feb-2017
2017/32922 (110421-0087-GC1)	E	Gulf Cooperative Council	National	HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS	12-Feb-2017
PCT/US2017/017408 (110421-0087-W01)	F	International	PCT	HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS	10-Feb-2017
11118 (110421-0087-LB1)	G	Lebanon	National	HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS	10-Feb-2017

60709523_1

88/2017 (110421-0087-PK1)	H	Pakistan	National	HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS	10-Feb-2017
2017-000056 (110421-0087-VE1)	I	Venezuela	National	HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS	10-Feb-2017
106104428 (110421-0087-TW1)	J	Taiwan	National	HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS	10-Feb-2017
18/1/5799 (110421-0087-JM1)	K	Jamaica	National	HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS	10-Feb-2017

60709523_1

PATENT

RECORDED: 09/12/2022

REEL: 061481 FRAME: 0104